实用医学杂志 ›› 2022, Vol. 38 ›› Issue (19): 2495-2500.doi: 10.3969/j.issn.1006⁃5725.2022.19.023

• 综述 • 上一篇    下一篇

地舒单抗治疗血液透析患者骨质疏松症的研究进展

李诗诗 刘璠娜    

  1. 广东省广州市暨南大学附属第一医院肾内科(广州 510000

  • 出版日期:2022-10-10 发布日期:2022-10-10
  • 通讯作者: 刘璠娜 E⁃mail:13560421216@126.com
  • 基金资助:
    2022 年广州市科技计划(编号:a01219);2021 年广东省普通高校重点领域专项(编号:2021ZDZX2042);广州市校(院)联合资助(登峰医院)基础研究项目(编号:202201020080)

Research progress of denosumab in the treatment of osteoporosis in hemodialysis patients

LI ShishiLIU Fanna.   

  1. Department of Nephrologythe First Affiliated Hospital of Ji′nan UniversityGuangzhou 510000China

  • Online:2022-10-10 Published:2022-10-10
  • Contact: LIU Fanna E⁃mail:13560421216@126.com

摘要:

骨质疏松症是骨矿物质密度低和微结构恶化导致骨强度低和骨折风险增加的疾病。肾功 能衰竭因为代谢紊乱会加速骨质流失,增加骨质疏松的风险进而导致骨折甚至死亡。地舒单抗作为核因 ⁃κ 因受体活化因子配体抑制剂,广泛应用于骨质疏松症的治疗。近年来,关于地舒单抗在血液透析患 者骨质疏松症中的应用越来越多。现将地舒单抗在血液透析患者骨质疏松症治疗中的应用及研究进展 进行综述。

关键词:

骨质疏松症, 血液透析, 地舒单抗

Abstract:

Osteoporosis is a disease where low bone mineral density and microstructure deterioration lead to low bone strength and high risk of fracture. Because metabolic disorders will accelerate bone loss and renal failurewhich can increase the risk of osteoporosis that will lead to fracture or even death. Denosumab is a receptor activator of nuclear factor⁃κB ligand inhibitor that is widely used in the treatment of osteoporosis. In recent yearsthere are increasing applications of denosumab in hemodialysis patients with osteoporosis. This paper reviews the application and research progress of denosumab in the treatment of osteoporosis in hemodialysis patients

Key words:

osteoporosis, hemodialysis, denosumab